Barclays lowered the firm’s price target on C4 Therapeutics (CCCC) to $5 from $10 and keeps an Overweight rating on the shares. The firm adjusted price targets in the biotechnology space as part of its 2026 outlook.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCCC: